Verona Pharma To Host Conference Call To Review Expanded Dataset From Rpl554 Phase 2b Clinical Trial In Copd Presented At Eur...

 
TIDMVRP 
 
   LONDON, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) 
(Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical 
company focused on developing and commercializing innovative therapies 
for respiratory diseases, announces today that Jan-Anders Karlsson, CEO 
of Verona Pharma, will host an investment community conference call 
detailing the expanded dataset from RPL554 Phase 2b clinical trial in 
COPD to be presented in an oral presentation at the European Respiratory 
Society International Congress on Monday, September 17 at 8:30 a.m. 
CEST. 
 
   The investment community call will take place at 8:00 a.m. Eastern 
Daylight Time (1:00 p.m. British Summer Time) on Tuesday, September 18, 
2018. Analysts and Investors may participate in the conference call by 
dialing the following numbers: 
 
 
   -- 1-877-423-9813 or 1-201-689-8573 for callers in the United States 
 
   -- 0 800 756 3429 for callers in the United Kingdom 
 
   -- 0 800 182 0040 for callers in Germany 
 
 
   Those interested in listening to the conference call live via the 
internet may do so by visiting the "Investors" page of Verona Pharma's 
website at 
https://www.globenewswire.com/Tracker?data=zwDtOuODp4UGjnGH2WjT16udO6CAtLxmo93PvtR7sGJoJcuvKae88Ff3dNLWWB1OALyf3hNRE2qVV1Zy2UeQnI6PdFCRjTLgpK6td3GS15U= 
www.veronapharama.com and clicking on the "Events and presentations" 
link. 
 
   A webcast replay of the conference call (audio) will be available for 30 
days on the "Investors" page of Verona Pharma's website at 
https://www.globenewswire.com/Tracker?data=zwDtOuODp4UGjnGH2WjT10HCs0cXbIBz2C34bm4-rgl-I2IVokO7rX4EkG8YXSrPkymBWOperJUPf8RbmtzaW56Ug3ArBx7gxy5Be9iUC2A= 
www.veronapharma.com. 
 
   About Verona Pharma plc and RPL554 
 
   Verona Pharma is a clinical-stage biopharmaceutical company focused on 
developing and commercializing innovative therapies for the treatment of 
respiratory diseases with significant unmet medical needs. Verona 
Pharma's product candidate, RPL554, is a first-in-class, inhaled, dual 
inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a 
bronchodilator and an anti-inflammatory agent in a single compound. In 
previous clinical trials, RPL554 has been observed to result in 
bronchodilator effects when used alone or as an add-on treatment to 
other COPD bronchodilators. It has shown clinically meaningful and 
statistically significant improvements in lung function when 
administered in addition to frequently used short- and long-acting 
bronchodilators, such as tiotropium (Spiriva(R)), compared with such 
bronchodilators administered as a single agent. RPL554 improved FEV(1) 
over four weeks in patients with moderate-to-severe COPD when compared 
to placebo and improved COPD symptoms and Quality of Life in a Phase 2b 
multicenter European study performed in 403 patients. In addition, 
RPL554 has shown anti-inflammatory effects in a standard challenge study 
with COPD-like inflammation in human subjects. RPL554 has been well 
tolerated in these studies and has a favorable safety and tolerability 
profile, having been administered to more than 730 subjects in 12 
clinical trials. Verona Pharma is developing RPL554 for the treatment of 
chronic obstructive pulmonary disease ("COPD"), cystic fibrosis ("CF"), 
and potentially asthma. 
 
   For further information, please contact: 
 
 
 
 
Verona Pharma plc                                  Tel: +44 (0)20 3283 4200 
Jan-Anders Karlsson, Chief Executive Officer       info@veronapharma.com 
 
Stifel Nicolaus Europe Limited (Nominated Adviser  Tel: +44 (0) 20 7710 7600 
 and UK Broker) 
Stewart Wallace / Jonathan Senior / Ben Maddison 
 
FTI Consulting (UK Media and Investor enquiries)   Tel: +44 (0)20 3727 1000 
Simon Conway / Natalie Garland-Collins             veronapharma@fticonsulting.com 
 
ICR, Inc. (US Media and Investor enquiries) 
James Heins                                        Tel: +1 203-682-8251 
                                                    James.Heins@icrinc.com 
Stephanie Carrington                               Tel. +1 646-277-1282 
                                                    Stephanie.Carrington@icrinc.com
(END) Dow Jones Newswires
September 13, 2018 08:00 ET (12:00 GMT)
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024